long absences between nrsto keep investor's interest in developments is all that is supporting the shareprice until such time as we get some real numbers for volume of sales and black ink.
Doesn't help that the market correction is lead by cannabis and hemp stocks and dissapointment of investors who are waiting on political change in the form of a "triggering event" that will clear the Senate.
Investors that are interested in this sector and understand the explosive potential may be moving on to better prospects or what they perceive as better prospects or they may be weak hands that need the money from their investment to deal with runaway inflation.
The prospect of rising interest rates always hurts the market and the slowdown caused by covid and supply problems that lead to delays and non-delivery of the normal supply chain.
There is also all of the newcomers that are throwing their hats into the cannabinoid business when even the giants of this industry are re-coiling, leaning out and swallowing up assets that will benefit them, for pennies, because they can.
Missing timeline expectations is more of a deathknell for small, underfinanced companies, especially those that think this is an easy segment to compete in.
One good product can make a company, so there is always hope if investors are nurtured with some positive, honest reporting of business affairs. Ignoring shareholders will kill a company faster than anything.
glta and dyodd